Basile A S, Ostrowski N L, Gammal S H, Jones E A, Skolnick P
Section on Neurobiology, NIDDK, National Institutes of Health, Bethesda, MD.
Adv Biochem Psychopharmacol. 1990;46:189-200.
The involvement of GABAergic systems in the pathogenesis of HE was supported by electrophysiologic studies of single Purkinje neurons from rabbits with HE which demonstrated the hypersensitivity of these neurons to depression by GABA and BZ receptor agonists. In contrast, these neurons were excited by BZ receptor antagonists. At concentrations which had no effect on neuronal activity, BZ receptor antagonists also reversed the hypersensitivity of HE neurons to depression by muscimol. This combination of neuronal responses is consistent with an increase in the concentration or availability of a ligand for the BZ receptor with agonist properties in the brains of rabbits with HE. Subsequent neurochemical studies support these electrophysiologic observations. Autoradiographic techniques indicated the presence of a reversible inhibitor of [3H]Ro 15-1788 and [3H]flunitrazepam binding to the cerebral and cerebellar cortices of rabbits with HE. The ability of this substance to inhibit [3H]flunitrazepam binding to HE rabbit brain sections was further enhanced in the presence of NaCl and GABA. The autoradiographic studies suggested that the density and affinity of the components of the GABA-BZ receptor complex are unaltered in this animal model of HE. This inference is fully supported by the subsequent studies of radioligand binding to well-washed membrane preparations. Finally, extracts of HE rabbit brains yielded a family of substances with the properties of BZ receptor agonists. These substances may include, but are not limited to, diazepam, oxazepam and desmethyldiazepam, but do not include substances commonly elevated in the plasma and CSF of patients with HE4. The positive identification of these substances awaits confirmation by mass-spectroscopic analysis. However, the precedent for the presence of a family of benzodiazepines in animals that were not administered these drugs has been set. The origin of these substances is a matter of ongoing research. Several studies have shown the presence of benzodiazepines in plant and animal materials. It is possible that these "endogenous" benzodiazepines are the result of contamination of the food chain. A normally functioning liver would capture and metabolize these compounds after their absorption from the gut. This function of the liver would be impaired in liver failure, thus allowing sufficient levels of BZ receptor agonists to accumulate in the CNS, contributing to the pathogenesis of HE. However, studies by DeBlas and coworkers have reported that 1,4 benzodiazepines are present in human brains preserved prior to the commercial use of these compounds. Further, they have found benzodiazepines in cell lines cultured without potential exogenous sources of benzodiazepines.(ABSTRACT TRUNCATED AT 400 WORDS)
GABA能系统参与肝性脑病发病机制的观点得到了对患肝性脑病兔子的单个浦肯野神经元的电生理研究的支持,这些研究表明这些神经元对GABA和苯二氮䓬受体激动剂诱导的抑制作用高度敏感。相反,这些神经元会被苯二氮䓬受体拮抗剂兴奋。在对神经元活动无影响的浓度下,苯二氮䓬受体拮抗剂还能逆转肝性脑病神经元对蝇蕈醇抑制作用的超敏反应。这种神经元反应的组合与患肝性脑病兔子大脑中具有激动剂特性的苯二氮䓬受体配体浓度或可用性增加一致。随后的神经化学研究支持了这些电生理观察结果。放射自显影技术表明,在患肝性脑病兔子的大脑和小脑皮质中存在一种对[³H]Ro 15 - 1788和[³H]氟硝西泮结合有可逆抑制作用的物质。在氯化钠和GABA存在的情况下,这种物质抑制[³H]氟硝西泮与肝性脑病兔子脑切片结合的能力进一步增强。放射自显影研究表明,在这种肝性脑病动物模型中,GABA - 苯二氮䓬受体复合物各成分的密度和亲和力未改变。随后对洗涤良好的膜制剂进行的放射性配体结合研究完全支持了这一推断。最后,患肝性脑病兔子大脑的提取物产生了一系列具有苯二氮䓬受体激动剂特性的物质。这些物质可能包括但不限于地西泮、奥沙西泮和去甲基西泮,但不包括肝性脑病患者血浆和脑脊液中通常升高的物质。这些物质的明确鉴定有待质谱分析确认。然而,在未施用这些药物的动物体内存在一系列苯二氮䓬类药物的先例已经确立。这些物质的来源是正在进行的研究课题。多项研究表明植物和动物材料中存在苯二氮䓬类药物。这些“内源性”苯二氮䓬类药物可能是食物链污染的结果。正常运作的肝脏会在这些化合物从肠道吸收后捕获并代谢它们。肝功能衰竭时肝脏的这种功能会受损,从而使足够水平的苯二氮䓬受体激动剂在中枢神经系统中积累,导致肝性脑病的发病机制。然而,德布拉斯及其同事的研究报告称,在这些化合物商业化使用之前保存的人脑中存在1,4 - 苯二氮䓬类药物。此外,他们在没有潜在苯二氮䓬类药物外源来源的情况下培养的细胞系中发现了苯二氮䓬类药物。(摘要截短于400字)